Preferences help
enabled [disable] Abstract
Number of results
2006 | 55 | 2-3 | 267-276
Article title

Nowotwory tarczycy — klasyczne techniki diagnostyczne i markery nowotworowe

Title variants
Thyroid neoplasms — classical diagnostic techniques and tumor markers
Languages of publication
Thyroid tumors are a very common disorder and can occur in six percent of human population. Despite this fact, there are still no effective and reliable techniques that would allow to pose a reliable differential diagnosis between malignant and benign thyroid tumor. The prevailing diagnostic techniques are: ultrasonography, scinthigraphy and fine needle aspiration cytology. In many cases they can not distinguish carcinomas from benign neoplasms. Such diagnosis is essential, because the patient with malignancy undergoes a very rigorous treatment that is unnecessary and inadvisable for patient with benign lesions. Therefore, the thyroid tumor markers are searched for. Generally tumor markers are substances, which presence or absence is related to malignancy. They can be used for population screening and for detection, diagnosis, staging, prognosis or follow up of malignant diseases. The thyroid tumor markers currently used have very restricted applications. The first one — calcitonine is produced only by one kind of cancer (medullary carcinoma) and the second — thyroglobulin is useful only in detection of recurrent follicular and papillary thyroid carcinoma. Therefore, there is a need to search for new tumor marker that could enable to differentiate benign lesions in thyroid from malignancies. This review article presents some information about thyroid neoplasms and methods of their diagnosis, highlighting current and possible usage of tumor markers.
Physical description
  • Akahani S., Inohara H., Nangia-Makk er P., Raz A., 1997. Galectin-3 in tumor metastasis. Trends Glycosc. Glycotech. 9, 69-75.
  • Braverman L. E., Utiger R. D., 1991. Werner and Ingbar‘ s The Thyroid: a fundamental and clinical text. J. B. Lippincott Company, Philadelphia. Chatziantoniou V. D., 2001. Telomerase: biological function and potential role in cancer managment. Pathol. Oncol. Res. 7, 161-170.
  • Cheung C. C., Ezzat S., Freeman J. L., Rosen I. B., Asa S. L., 2001. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod. Pathol. 14, 338-342.
  • Clayman G. L., El-Baradie T. S., 2003. Medullary thyroid cancer. Otolaryngol. Clin. North Am. 36, 91-105.
  • Cvejić D., Savin S., Petrović I., Paunović I., Tatić S., Havelka M., 2003. Galectin-3 expression in medullary thyroid carcinoma in relation to tumor progression. Arch. Oncol. 11, 71-74.
  • Del Hayo J. (red.), 2001. Wielki leksykon zdrowia i medycyny. Grupa Wydawnicza Bertelsmann Media Świat Książki, Warszawa.
  • Gimm O., 2001. Thyroid cancer. Cancer Lett. 163, 143-156.
  • Górowski T., 1989. Choroby tarczycy. Państwowy Zakład Wydawnictw Lekarskich, Warszawa Hirsch P. F., Baruch H., 2003. Is calcitonin an important physiological substance? Endocrine 21, 201-208.
  • Kholova I., Ludvikova M., Ryska A., Topolcan O., Pikner R., Pecen L., Cap J., Holubec J. R., 2003. Diagnostic role of markers dipeptidyl peptidase IV and thyroid peroxidase in thyroid tumors. Anticancer Res. 23, 871-876.
  • Kholova I., Ryska A., Ludvikova M., Cap J., Pecen L., 2003. Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study. Cytopathology 14, 27-31.
  • Kilicarslan A. B., Ogus M., Arici C., Pestereli H. E., Cakir M., Karpuzoglu G., 2003. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinoma. APMIS 111, 439-443.
  • Klein M., Vignaud J. M., Hennequin V., Toussaint, Bresler L., Plenat F., Leclere J., Duprez A. Weryha G., 2001. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 86, 656-658.
  • La S., Cho J., Kim J. H., Kim K. R., 2003. Capillary electrophoretic profiling and pattern recognition analysis of urinary nucleosides from thyroid cancer patients. Anal. Chim. Acta 486, 171-182.
  • Liebich H. M., Muller-Hagedorn S. M., Klaus F., Meziane K., Kim K. R., Frickenschmidt A., Kammerer B., 2005. Chromatographic, capillary electrophoretic and matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis of urinary modified nucleosides as tumor markers. J. Chromatogr. A 1071, 271-275.
  • Lin J. D., 1999. Diagnosis of papillary and follicular thyroid cancers. Chang Gung Med. J. 22, 348-361.
  • Lindb lom A., Liljegren A., 2000. Tumor markers in malignancies. BMJ 320, 424-427.
  • Lips C. J. M., Hopp ener J. W. H., Thijssen J. H. H., 2001. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann. Clin. Biochem. 38, 168-179.
  • Łącka K., 1997. Choroby tarczycy. Springer PWN, Warszawa.
  • Matesa N., Dabelić N., Tabain I., Kusić Z., 2002. Fine needle aspiration of the thyroid. Acta Clin. Croat. 41, 123-131.
  • Matthews P., Jones C. J., Skinner J., Haugh ton M., De Micco C., Wynford-Thomas D., 2001. Telomerase avtivity and telomere lenght in thyroid neoplasia: biological and clinical implications. J. Pathol. 194, 183-193.
  • Mokh tari M., Sadegh i M., Talebi A., 2005. Monoclonal antibody HBME-1 usefulness in differentation of bening neoplasm and differantiated thyroid carcinoma. Acta Med. Iran. 43, 85-88.
  • Mora J., Lerma E., 2004. Telomerase activity in thyroid fine needle aspirates. Acta Cytol. 48, 818-824.
  • Patel A., Jhiang S., Dogra S., Terrell R., Powers P. A., Fenton C., Dinauer C. a., Tuttle R. m., Francis G. L., 2002. Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents. Pediatr. Res. 52, 737-744.
  • Ringel M., 2000. Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma. Rev. Endocr. Metab. Disord. 1, 173-181.
  • Schlumberger M., Baudin E., 1998. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 138, 249-252.
  • Sherman S. I., 2003. Thyroid carcinoma. Lancet 361, 501-511.
  • Soh E. Y., Duh Q. Y., Sobh i S. A., Young D. M., Epstein H. D., Wong M. G., Garcia K., Min Y. D., Grossman R. F., Siperstein A. E., Clark O. H., 1997. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or bening thyroid. J. Clin. Endocrinol. Metab. 82, 3741-3745.
  • Sturgeon C., 2002. Practice guidelines for tumor marker use in the clinic. Clin. Chem. 48, 1151-1159.
  • Suzuki S., Fukushima T., Ami H., Onogi H., Nakamura I., Takenoshita S., 2002. New attempt of preoperative differential diagnosis of thyroid neoplasms by telomerase activity measurement. Oncol. Rep. 9, 539-544.
  • Trulsson L. M., Velin A. K., Herder A., Soderkvist P., Ruter A., Smeds S., 2003. Telomerase activity in surgical specimens and fine-needle aspiration biopsies from hyperplastic and neoplastic human thyroid tissues. Am. J. Surg. 186, 83-88.
  • Tuttle R. M., Fleisher M., Francis G. L., Robb ins R. J., 2002. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J. Clin. Endocrinol. Metab. 87, 1737-1742.
  • Woyke S., Olszewski W., 1982. Cytodiagnostyka aspiracyjna nowotworów. Wydawnictwo Lekarskie PZWL , Warszawa.
  • Zgliczyński S., 2001. Choroby tarczycy. Wydawnictwo Medyczne Urban & Partner, Wrocław.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.